AlpInvest leads €600m GP-led on specialty pharma asset

Swiss GP Gyrus Capital originally invested in Essential Pharma in 2019 as part of a family/founder succession plan process.

SECONDARIES INVESTOR

Register to unlock this content

• Daily global secondaries market news and intelligence
• Curated insights to keep you ahead of GP-led and LP-led secondaries
• Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
• Access to proprietary research and reports
• Selected fund performance and investor activity data

Register nowFind out more

DealsWestern EuropeHealthcareSingle AssetsFeatured